AbbVie Inc. is 343.6x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($399.47 B vs $1.16 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | XERS | ABBV |
|---|---|---|
| Market cap | $1.16 B | $399.47 B |
| US-listed rank | #2530 | #28 |
| Revenue (latest FY) | $291.85M | $61.16B |
| Net income (latest FY) | $554.00K | $4.23B |
| Net margin | 0.2% | 6.9% |
| P/E (trailing FY) | 2098.8 | 94.5 |
| SEC filings | 290 | 1,008 |
AbbVie Inc. is 343.6x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($399.47 B vs $1.16 B).
In their latest fiscal years, Xeris Biopharma Holdings, Inc. reported $291.85M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Xeris Biopharma Holdings, Inc. and AbbVie Inc., or browse the full rankings.